Tipping Point: Tariffs Create Uncertainty, Risk Long-Term Price Increases, Shortages

President Trump’s 10% tariff on active pharmaceutical ingredients and finished dosage forms could push some generic drug makers to exit therapeutic categories if they cannot absorb the new costs, which could lead to shortages.

Egg on table edge
The 10% tariff on API from China, if it lasts, could push some generic drug manufacturers out of some markets. (Shutterstock)

President Donald Trump’s decision to impose a 10% tariff on pharmaceuticals and other goods imported from China may have little short-term impact on the drug supply and prices in the US.

More from Distribution/Supply Chain

More from Biosimilars & Generics